SLC5A2 and type 2 diabetes mellitus: This comparative effectiveness study evaluates cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in adults with type 2 diabetes overall and at varying baseline HbA1c levels.